26 October 2023 – 1 mins read
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today presents its sales performance for the year to date and the third quarter of 2023.
Showing: 1 – 05 of 23 Financial Results
Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance
Paris (France), 22 October 2020 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2020.
Ipsen presents its half year 2020 results and reinstates guidance for full year 2020
David Loew, Chief Executive Officer of Ipsen, stated: “I’m honored since July 1st to lead Ipsen, an exciting global biopharma business with solid business fundamentals, a strong purpose to serve patients and attractive growth opportunities. I am encouraged by the exceptional levels…
Ipsen reports solid sales growth in first quarter 2020 with limited COVID-19 impact
Paris (France), 22 April 2020 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its sales for the first quarter of 2020.